New Delhi: In a major setback to drug major, Biocon, the National Task Force on COVID-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said.Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of...
New Delhi: In a major setback to drug major, Biocon, the National Task Force on COVID-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said.
Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of Biocon, used for treating psoriasis -- a skin condition -- was approved for "restricted emergency use" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) recently.
Medical Dialogues had earlier reported that Biocon had repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19.
Also Read: Biocon Itolizumab Gets DCGI Nod To Treat COVID-19 Patients
The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Distress Syndrome patients due to COVID-19.
"The issue of including the drug in the clinical protocols was discussed in a meeting held on Friday. A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19," said an official source.
As per a recent PTI report, the domestic biopharmaceutical company, Biocon, has been manufacturing and marketing Itolizumab, a monoclonal antibody, for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013, under the brand name ALZUMAb, the Union health ministry had earlier said.
However, a Biocon spokesperson said, "The National COVID Task Force needs to see more evidence and we will provide them large real-world data to enable the committee to reconsider its decision on inclusion of Itolizumab in the protocol."
"Nearly 1,000 patients have used the drug across the country with good outcome data," the company spokesperson said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd